$-0.58 EPS Expected for G1 Therapeutics, Inc. (GTHX)

January 23, 2018 - By Maria Brooks

 $ 0.58 EPS Expected for G1 Therapeutics, Inc. (GTHX)

Analysts expect G1 Therapeutics, Inc. (NASDAQ:GTHX) to report $-0.58 EPS on February, 14.After having $-0.55 EPS previously, G1 Therapeutics, Inc.’s analysts see 5.45 % EPS growth. The stock decreased 3.76% or $0.99 during the last trading session, reaching $25.35. About 159,757 shares traded or 3.93% up from the average. G1 Therapeutics, Inc. (NASDAQ:GTHX) has 0.00% since January 23, 2017 and is . It has underperformed by 16.70% the S&P500.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. The company has market cap of $718.55 million. It is developing trilaciclib, an intravenous cyclin-dependent kinases 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. It currently has negative earnings. The firm has a clinical trial collaboration agreement with AstraZeneca to evaluate AstraZeneca??s epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Tagrisso (osimertinib) in combination with oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer; and a research partnership GeneCentric Therapeutics, Inc. to identify subtypes of lung cancer where the compound is likely to be efficacious.

More notable recent G1 Therapeutics, Inc. (NASDAQ:GTHX) news were published by: Marketwatch.com which released: “G1 Therapeutics Inc.” on April 14, 2017, also Globenewswire.com with their article: “G1 Therapeutics Makes Key Appointments to Management Team” published on August 03, 2017, Seekingalpha.com published: “Stay Away From The G1 Therapeutics IPO” on May 22, 2017. More interesting news about G1 Therapeutics, Inc. (NASDAQ:GTHX) were released by: Globenewswire.com and their article: “G1 Therapeutics to Present at 36th Annual JP Morgan Healthcare Conference” published on January 02, 2018 as well as Seekingalpha.com‘s news article titled: “G1 Therapeutics Inc. Plans To Go Public In Its Early Stages” with publication date: May 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.